Skip directly to site content
Are You Still There?
Due to inactivity, you will be signed out in two minutes unless you click 'Continue'.

Are you still there?

Due to inactivity, you will be signed out in two minutes unless
you click 'Continue'.

Panel:   ARBank custom (n=29) (Custom)
AR Bank # 0118 Escherichia coli
Study ID: CRE-07

Biosample Accession #: SAMN04014959

MICs obtained by broth microdilution. Modal MIC is reported.

Panel:  Enterobacterales Carbapenemase Diversity (CRE)  |  Cefiderocol Verification (FDC) (Custom)


MIC (μg/ml) Results and Interpretation
Drug MIC (μg/ml) INT
Amikacin >64R
Ampicillin >32R
Ampicillin/sulbactam 1>32R
Aztreonam 64R
Aztreonam/avibactam 1 42S
Cefazolin >32R
Cefepime >32R
Cefiderocol >32R
Cefotaxime >64R
Cefotaxime/clavulanic acid 1>32---
Cefoxitin >16R
Ceftazidime >128R
Ceftazidime/avibactam 1>16R
Ceftazidime/clavulanic acid 1>64---
Ceftolozane/tazobactam 1>16R
Ceftriaxone >32R
Ciprofloxacin >8R
Colistin 20.5I
Doripenem >8R
Ertapenem >8R
Gentamicin >16R
Imipenem 16R
Imipenem+chelators 30.5---
Levofloxacin >8R
Meropenem >8R
Meropenem-vaborbactam 1>16R
Piperacillin/tazobactam 1>128R
Tetracycline <=2S
Tigecycline 4<=0.5S
Tobramycin >16R
Trimethoprim/sulfamethoxazole 1>8R
SDD (Susceptible Dose Dependent)
S – I –R Interpretation (INT) derived from CLSI 2025 M100 S35
1 Reflects MIC of first component
2 Clinical and PK/PD data demonstrate colistin has limited clinical efficacy, even if an intermediate result is obtained. Alternative agents are strongly preferred. Colistin should be used in combination with one or more active antimicrobial agents. Consultation with an infectious disease specialist is recommended.
3 Screen for metallo-beta-lactamase production [Rasheed et al. Emerging Infectious Diseases. 2013. 19(6):870-878]
4 Based on FDA break points
Device manufacturers and users of FDA cleared devices shall consult the FDA’s Antibacterial Susceptibility Test Interpretive Criteria       website for breakpoints recognized or recommended by FDA, and for information regarding FDA exceptions or additions to the applicable, recognized consensus standard.
Molecular Mechanisms of Resistance
CategoryGene
Aminoglycoside aac(3)-IIa, rmtC, strA, strB
Beta-lactam NDM-1, CMY-6, OXA-2, TEM-1A
Phenicols/Bicyclomycins catA1
Sulfonamides sul1
Trimethoprim dfrA29
Truncated Porin OmpF
 
Disclaimer:
No disclaimer.
Propagation
MEDIUM
Medium: Trypticase Soy Agar with 5% Sheep Blood (BAP)

GROWTH CONDITIONS
Temperature: 35°C
Atmosphere: Aerobic

PROPAGATION PROCEDURE

Remove the sample vial to a container with dry ice or a freezer block. Keep vial on ice or block. (Do not let vial content thaw)

Open vial aseptically to avoid contamination

Using a sterile loop, remove a small amount of frozen isolate from the top of the vial

Aseptically transfer the loop to BAP

Use streak plate method to isolate single colonies

Incubate inverted plate at 35°C ± 2°C for 18-24 hrs.
Storage Temperature & Biosafety
STORAGE TEMPERATURE: -70°C

BIOSAFETY LEVEL: 2

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the current publication of 'BioSafety in Microbiological and Biomedical Laboratories' from the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, and National Institutes of Health.



Disclaimer:

Isolate History
Date Action Performed
03/14/25INT was updated with a new value for Aztreonam/avibactam: from '---' to 'S'
03/14/25MIC was updated with a new value for Aztreonam/avibactam: from '---' to '2'
Top of Page
TOP